Pierre Blanchard: Another Proof That Metastasis-Directed Therapy Improves Outcomes
Pierre Blanchard, Editor in Chief of Radiotherapy and Oncology, aka Green Journal, Radiation Oncologist at Gustave Roussy, shared a post on X:
“Another proof that metastasis directed therapy improves outcomes, this time in castration resistant prostate cancer.
Congrats to the PCS IX team!”
Title: Metastases-directed therapy in addition to standard systemic therapy in oligometastatic castration-resistant prostate cancer in Canada (GROUQ-PCS 9): a multicentre, open-label, randomised, phase 2 trial
Authors: Tamim Niazi, Fred Saad, Steven Tisseverasinghe, Rashmi Koul, Isabelle Thibault, Peter W M Chung, George Wakil, Michael Lock, Guila Delouya, Boris Bahoric, Andrew Feifer, Venkata Ramana Agnihotram, Theodoros Tsakiridis, Fabio L Cury, Rafika Dahmane, Nikhilesh Gajanan Patil, Scott Tyldesley
Read The Full Article at The Lancet Oncology.
More posts featuring Pierre Blanchard.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023